Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Income from Continuing Operations (2016 - 2025)

Kiora Pharmaceuticals' Income from Continuing Operations history spans 11 years, with the latest figure at 6498670.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 53.87% year-over-year to 6498670.0; the TTM value through Dec 2025 reached 10817303.0, down 400.92%, while the annual FY2025 figure was 10817303.0, 400.92% down from the prior year.
  • Income from Continuing Operations reached 6498670.0 in Q4 2025 per KPRX's latest filing, down from 26806.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 13453207.0 in Q1 2024 to a low of 14391768.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 2561822.47, with a median of 2469298.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: tumbled 1126.36% in 2021, then surged 801.91% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 14391768.0 in 2021, then skyrocketed by 74.26% to 3703972.0 in 2022, then surged by 43.87% to 2079108.0 in 2023, then plummeted by 103.14% to 4223502.0 in 2024, then tumbled by 53.87% to 6498670.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Income from Continuing Operations are 6498670.0 (Q4 2025), 26806.0 (Q3 2025), and 2152459.0 (Q2 2025).